A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer’s Disease
E2020-C086-339
Study Overview
E2020
donepezil
NCT01404169
Sep 2011 - Jul 2014
Alzheimer's disease
To demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo for changes from Baseline to Week 24 in cognitive function in Chinese participants with severe Alzheimer's disease.
Male and female patients (aged 50 to 90 years)
Completed
Phase
3
China
Results
CSR Synopsis
No download available
Lay Summary
No download available
Publication reference citation
Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, et al. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer’s Disease: A Randomized Controlled Trial. Journal of Alzheimer’s Disease. 2017;56:1495-504.
Data Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
Redacted documents are available upon request for this study.